159 related articles for article (PubMed ID: 14758735)
1. GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases.
Nikolettos N; Asimakopoulos B; Simopoulou M; al-Hasani S
In Vivo; 2003; 17(6):655-8. PubMed ID: 14758735
[TBL] [Abstract][Full Text] [Related]
2. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
3. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
5. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
[TBL] [Abstract][Full Text] [Related]
6. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
7. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
[TBL] [Abstract][Full Text] [Related]
8. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
9. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study.
Ata B; Yakin K; Balaban B; Urman B
Hum Reprod; 2008 Mar; 23(3):668-73. PubMed ID: 18192671
[TBL] [Abstract][Full Text] [Related]
10. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support.
Imbar T; Kol S; Lossos F; Bdolah Y; Hurwitz A; Haimov-Kochman R
Hum Reprod; 2012 Mar; 27(3):753-9. PubMed ID: 22252086
[TBL] [Abstract][Full Text] [Related]
11. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
[TBL] [Abstract][Full Text] [Related]
12. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos.
Endo T; Honnma H; Hayashi T; Chida M; Yamazaki K; Kitajima Y; Azumaguchi A; Kamiya H; Kudo R
Hum Reprod; 2002 Oct; 17(10):2548-51. PubMed ID: 12351526
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
[TBL] [Abstract][Full Text] [Related]
14. Ovarian hyperresponse to luteal phase GnRH-agonist administration.
Depenbusch M; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2010 Jun; 281(6):1071-2. PubMed ID: 19960348
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation.
Tesarik J; Hazout A; Mendoza C
Hum Reprod; 2004 May; 19(5):1176-80. PubMed ID: 15070873
[TBL] [Abstract][Full Text] [Related]
16. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases.
Gurbuz AS; Gode F; Ozcimen N; Isik AZ
Reprod Biomed Online; 2014 Nov; 29(5):541-4. PubMed ID: 25246114
[TBL] [Abstract][Full Text] [Related]
17. Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome.
Friedler S; Grin L
Gynecol Endocrinol; 2019 May; 35(5):368-369. PubMed ID: 30614333
[TBL] [Abstract][Full Text] [Related]
18. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
[TBL] [Abstract][Full Text] [Related]
19. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.
Hernández ER; Gómez-Palomares JL; Ricciarelli E
Fertil Steril; 2009 Apr; 91(4 Suppl):1358-61. PubMed ID: 18555236
[TBL] [Abstract][Full Text] [Related]
20. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
